BIOMAT Database Logo BIOMAT Database Logo

Absolute structure-cytotoxic activity relationships of steganacin congeners and analogues. 1991

K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

The cytotoxic activities of optically pure and racemic steganacin congeners and analogues against KB cells in culture and the inhibitor activity of cilia regeneration in Tetrahymena were studied with regard to absolute and relative configurations. The stereochemical requirements of dibenzocyclooctadiene lignan lactones for activity were clarified.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D007624 KB Cells This line KB is now known to be a subline of the ubiquitous KERATIN-forming tumor cell line HeLa. It was originally thought to be derived from an epidermal carcinoma of the mouth, but was subsequently found, based on isoenzyme analysis, HeLa marker chromosomes, and DNA fingerprinting, to have been established via contamination by HELA CELLS. The cells are positive for keratin by immunoperoxidase staining. KB cells have been reported to contain human papillomavirus18 (HPV-18) sequences. HeLa-KB Cells,Cell, HeLa-KB,Cell, KB,Cells, HeLa-KB,Cells, KB,HeLa KB Cells,HeLa-KB Cell,KB Cell
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015107 4-Butyrolactone One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent. 1,4-Butanolide,4-Hydroxybutyric Acid Lactone,Furanone, tetrahydro-2-,gamma-Butyrolactone,Dihydro-2(3H)-furanone,1,4 Butanolide,4 Butyrolactone,4 Hydroxybutyric Acid Lactone,Furanone, tetrahydro 2,Lactone, 4-Hydroxybutyric Acid,gamma Butyrolactone
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Structure--antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (+/-)-isodeoxypodophyllotoxin.
May 1980, Journal of medicinal chemistry,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Synthesis, cytotoxic activity and structure-activity relationships of hedychenone analogues.
April 2010, Bioorganic & medicinal chemistry letters,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Heteroaryl analogues of AMPA. 2. Synthesis, absolute stereochemistry, photochemistry, and structure-activity relationships.
July 1998, Journal of medicinal chemistry,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents.
September 2004, Bioorganic & medicinal chemistry letters,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Fluorescence properties of pseudomorphine and congeners: structure-activity relationships.
May 1980, Journal of pharmaceutical sciences,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Neurotensin analogues. Structure--activity relationships.
November 1977, Journal of medicinal chemistry,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Thalidomide-type teratogenicity: structure-activity relationships for congeners.
November 2018, Toxicology research,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Structure-activity relationships of kadsurenone analogues.
January 1987, Journal of medicinal chemistry,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Structure--activity relationships of nogalamycin analogues.
May 1982, Journal of medicinal chemistry,
K Tomioka, and T Ishiguro, and H Mizuguchi, and N Komeshima, and K Koga, and S Tsukagoshi, and T Tsuruo, and T Tashiro, and S Tanida, and T Kishi
Structure-activity relationships of ustiloxin analogues.
April 2011, Tetrahedron letters,
Copied contents to your clipboard!